Gemini Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2021. For the quarter, the company reported loss from operations of $16,490,000 compared to $9,631,000 a year ago. Net loss and comprehensive loss was $19,048,000 compared to $9,746,000 a year ago. Net loss per share attributable to common stockholders, basic and diluted was $0.59 compared to $0.67 a year ago.